AHMED NAWSHER ALAM

Dr. AHMED NAWSHER ALAM

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FCFergus J. Chadwick
Fergus J. Chadwick
JCJessica Clark
Jessica Clark
SCShayan Chowdhury
Shayan Chowdhury
TCTasnuva Chowdhury
Tasnuva Chowdhury
DPDavid John Pascall
David John Pascall
ASAyesha Sania
Ayesha Sania
Diagnostics for COVID-19 detection are limited in many settings. Syndromic surveillance is often the only means to identify cases but lacks specificity. Rapid antigen testing is inexpensive and easy-to-deploy but can lack sensitivity. We examine how combining these approaches can improve surveillance for guiding interventions in low-income communities in Dhaka, Bangladesh. Rapid-antigen-testing with PCR validation was performed on 1172 symptomatically-identified individuals in their homes. Statistical models were fitted to predict PCR-status using rapid-antigen-test results, syndromic data, and their combination. Under contrasting epidemiological scenarios, the models’ predictive and classification performance was evaluated. Models combining rapid-antigen-testing and syndromic data yielded equal-to-better performance to rapid-antigen-test-only models across all scenarios with their best performance in the epidemic growth scenario. These results show that drawing on complementary strengths across rapid diagnostics, improves COVID-19 detection, and reduces false-positive and -negative diagnoses to match local requirements; improvements achievable without additional expense, or changes for patients or practitioners.

6 September 2023 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
TITaufiqul Islam
Taufiqul Islam
SHSonia Tara Hegde
Sonia Tara Hegde
AKAshraful Islam Khan
Ashraful Islam Khan
TBTaufiqur Rahman Bhuiyan
Taufiqur Rahman Bhuiyan
ZKZahid Hasan Khan
Zahid Hasan Khan
FQFirdausi Qadri
Firdausi Qadri
: Despite focusing on cholera burden, epidemiologic studies in Bangladesh tend to be limited in geographic scope. National-level cholera surveillance data can help inform cholera control strategies and assess the effectiveness of preventive measures. Hospital-based sentinel surveillance among patients with suspected diarrhea in different sites across Bangladesh has been conducted since 2014. We selected an age-stratified sample of 20 suspected cholera cases each week from each sentinel site, tested stool for the presence of Vibrio cholerae O1/O139 by culture, and characterized antibiotic susceptibility in a subset of culture-positive isolates. We estimated the odds of being culture positive among suspected cholera cases according to different potential risk factors. From May 4, 2014 through November 30, 2021, we enrolled 51,414 suspected cases from our sentinel surveillance sites. We confirmed V. cholerae O1 in 5.2% of suspected cases through microbiological culture. The highest proportion of confirmed cholera cases was from Chittagong (9.7%) and the lowest was from Rangpur Division (0.9%). Age, number of purges, duration of diarrhea, occupation, and season were the most relevant factors in distinguishing cholera-positive suspected cases from cholera-negative suspected cases. Nationwide surveillance data show that cholera is circulating in Bangladesh and the southern region is more affected than the northern region. Antimicrobial resistance patterns indicate that multidrug resistance (resistance to three or more classes of antibiotics) of V. cholerae O1 could be a major threat in the future. Alignment of these results with Bangladesh’s cholera-control program will be the foundation for future research into the efficacy of cholera-control initiatives.

2 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
FKFarhana Khanam
Farhana Khanam
TITaufiqul Islam
Taufiqul Islam
FAFaisal Ahmmed
Faisal Ahmmed
SAShams Uddin Ahmed
Shams Uddin Ahmed
IHIsmail Hossen
Ismail Hossen
FQFirdausi Qadri
Firdausi Qadri
Background: From May to December 2021, Bangladesh experienced a major surge in the Delta variant of SARS-CoV-2. The earlier rollout of several vaccines offered the opportunity to evaluate vaccine effectiveness against this variant. Methods: A prospective, test-negative case-control study was conducted in five large hospitals in Dhaka between September and December 2021. The subjects were patients of at least 18 years of age who presented themselves for care, suffering COVID-like symptoms of less than 10 days’ duration. The cases had PCR-confirmed infections with SARS-CoV-2, and up to 4 PCR test-negative controls were matched to each case, according to hospital, date of presentation, and age. Vaccine protection was assessed as being the association between the receipt of a complete course of vaccine and the occurrence of SARS-CoV-2 disease, with symptoms beginning at least 14 days after the final vaccine dose. Results: In total, 313 cases were matched to 1196 controls. The genotyping of case isolates revealed 99.6% to be the Delta variant. Receipt of any vaccine was associated with 12% (95% CI: −21 to 37, p = 0.423) protection against all episodes of SARS-CoV-2. Among the three vaccines for which protection was evaluable (Moderna (mRNA-1273); Sinopharm (Vero Cell-Inactivated); Serum Institute of India (ChAdOx1 nCoV-19)), only the Moderna vaccine was associated with significant protection (64%; 95% CI: 10 to 86, p = 0.029). Protection by the receipt of any vaccine against severe disease was 85% (95% CI: 27 to 97, p = 0.019), with protection estimates of 75% to 100% for the three vaccines. Conclusions: Vaccine protection against COVID-19 disease of any severity caused by the Delta variant was modest in magnitude and significant for only one of the three evaluable vaccines. In contrast, protection against severe disease was high in magnitude and consistent for all three vaccines. Because our findings are not in complete accord with evaluations of the same vaccines in more affluent settings, our study underscores the need for country-level COVID-19 vaccine evaluations in developing countries.

1 January 2020 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
TSTahmina Shirin
Tahmina Shirin
TBTaufiqur R. Bhuiyan
Taufiqur R. Bhuiyan
RCRichelle C. Charles
Richelle C. Charles
SAShaheena Amin
Shaheena Amin
IBImran Bhuiyan
Imran Bhuiyan
FQFirdausi Qadri
Firdausi Qadri
Studies on serologic responses following COVID-19 have been published primarily in individuals who are moderately or severely symptomatic, but there are few data from individuals who are only mildly symptomatic or asymptomatic. To generate such data, we used World Health Organization disease severity categorization, and measured IgG, IgM, and IgA antibodies to the receptor binding domain (RBD) of spike protein of SARS-CoV-2 by ELISA in infected individuals, both mildly symptomatic (n=108) and asymptomatic (n=63) on days 1, 7, 14, and 30 following RT-PCR-based confirmation of infection in Bangladesh, and compared these results to those detected in pre-pandemic samples, including healthy controls (n=73) and individuals infected with other viruses commonly seen in this area (n = 79). Mildly symptomatic individuals developed IgM and IgA antibody responses by day 14 after detection of infection in 72% and 83% of individuals, respectively, while 95% of these individuals developed an IgG antibody response by day 14, and rose to 100% by day 30. In contrast, individuals infected with SARS-CoV-2 but who remained asymptomatic developed antibody responses significantly less frequently, with only 20% positive for IgA by day 14, 22% positive for IgM by day 14, and 45% positive for IgG by day 30 after detection of infection. These results confirm that immune responses are generated following COVID in individuals who develop mildly symptomatic illness. However, those with asymptomatic infection do not respond or have lower antibody levels. These results will impact modelling needed for determining herd immunity generated by natural infection or vaccination. Funding Statement: World Health Organization, Fogarty International Center TW005572 and Emerging Global Leader Award; K43 TW010362, the Fondation Merieux and the Bill and Melinda Gates Foundation (BMGF). This study was carried out with the support of the United States Agency for International Development (USAID) under the terms of USAID’s Alliance for Combating TB in Bangladesh activity cooperative agreement no. CA # 72038820CA00002. Declaration of Interests: The authors declare no conflict of interest. Ethics Approval Statement: The study was also approved by the IRB of the IEDCR and icddr,b.

15 June 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
MAMarjahan Akhtar
Marjahan Akhtar
Md. Rashedul IslamMd. Rashedul Islam
Md. Rashedul Islam
ZKZahid Hasan Khan
Zahid Hasan Khan
AAAfroza Akter
Afroza Akter
ITImam Tauheed
Imam Tauheed
FQFirdausi Qadri
Firdausi Qadri
Background: The dynamics of humoral immune responses following primary and booster COVID-19 vaccinations are crucial to understand in order to optimize vaccination strategies. This study evaluates the magnitude and durability of SARS-CoV-2-specific IgG antibody responses across different vaccines in a large cohort of Bangladeshi adults. Methods: A total of 6300 adults from nine hospitals across eight divisions of Bangladesh were enrolled. Participants received two primary doses of either ChAdOx1 nCoV-19 (Covishield, Serum Institute of India, n = 2855), mRNA-1273 (Moderna, n = 578), BNT162b2 (Pfizer-BioNTech, n = 121), or Vero-cell-inactivated (Sinopharm, n = 2746) vaccines. Booster doses were administered at one-year intervals post-primary vaccination. SARS-CoV-2 spike receptor-binding domain (RBD)-specific IgG antibody responses were measured by ELISA using serum from vaccinees at multiple time points after two primary and two booster doses. Results: A total of 3745 individuals received booster 1 (third dose), with 59% receiving heterologous boosters (a different vaccine regimen than the primary doses). Only 5.5% (n = 347) of participants received a second booster one year after the first booster (among them, 99% received BNT162b2). Our results suggest that heterologous boosters with the mRNA vaccine induced higher IgG levels than homologous boosters for individuals who received primary vaccination with adenovirus vector-based ChAdOx1 nCoV-19 or a Vero-cell-inactivated vaccine. However, in those who initially received the mRNA-based vaccine, both homologous and heterologous boosters produced comparable IgG responses. Among all vaccine types, booster immunization with the Vero-cell-inactivated vaccine induced the lowest antibody responses. Longitudinal analysis demonstrated significantly high IgG levels over the 12 months following the first booster (p < 0.0001); however, IgG levels declined significantly after the second booster dose (fourth dose). Conclusions: Heterologous boosting strategies, particularly those involving mRNA vaccines, elicit stronger and more sustained IgG responses compared to a homologous booster. However, antibody waning after the second booster highlights the need for continued monitoring and potential additional vaccine strategies.

24 June 2026 in Outbreak, Surveillance, Investigation & Response (OSIR) Journal
Verified
Journal Article
Open access
JRJahidur Rahman
Jahidur Rahman
MBMasum Billah
Masum Billah
MRMahbubur Rahman
Mahbubur Rahman
AHAlden Henderson
Alden Henderson
IMImmamul Muntasir
Immamul Muntasir
TSTahmina Shirin
Tahmina Shirin
Objectives: Diarrhea is a major health problem in Barisal, a coastal division of southern Bangladesh. In April 2021 a diarrheal outbreak was notified from Barisal health authorities. An investigation team was deployed to describe demographic characteristics and seasonal patterns, identify risk factors of diarrhea in the district, and implement control measures. Methods: We analyzed seasonality using district health information system for the period 2018–2021 and conducted a matched case-control study in Bakerganj, the most affected sub-district. Cases were residents reporting ≥3 loose watery stools within 24 hours during 18 Apr 2021–1 May 2021. Controls were randomly selected from neighbors of a case without any diarrheal illness. Descriptive statistics were used to summarize demographic characteristics and seasonal trends, and multivariable conditional logistic regression was used to assess associations between potential risk factors and diarrheal illness. Results: A total of 1,027 diarrheal cases were identified during the outbreak in Bakerganj. Cases increased annually in March (pre-monsoon season) and declined from June (monsoon season). We enrolled 66 cases and 132 matched controls. Drinking untreated surface water (adjusted odds ratio [AOR] 11.6, 95% confidence interval [CI] 2.4–56.3), preparing overnight fermented rice (AOR 2.5, 95% CI 1.1–5.3), and performing ablution (AOR 2.4, 95% CI 1.0–5.9) were significant risk factors. Using surface water treated by aluminum potassium sulfate was protective (AOR 0.3, 95% CI 0.1–0.7). Among stool samples, 27% (20/75) tested positive for Vibrio cholerae by rapid diagnostic test and 29% (11/38) by culture; 5 of 8 surface water samples tested were positive. Public Health Recommendations: This outbreak occurred before the monsoon and was linked to untreated surface water for drinking and household activities. Public health authorities should implement preventive measures to ensure safe drinking water and distribute sufficient amounts of aluminum potassium sulfate to treat surface water before the annual surge.